{"id":45432,"date":"2025-10-31T15:58:43","date_gmt":"2025-10-31T07:58:43","guid":{"rendered":"https:\/\/flcube.com\/?p=45432"},"modified":"2025-10-31T15:58:44","modified_gmt":"2025-10-31T07:58:44","slug":"gilead-sciences-reports-3-yoy-q3-2025-revenue-growth-hiv-sales-up-4","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=45432","title":{"rendered":"Gilead Sciences Reports 3% YoY Q3\u202f2025 Revenue Growth, HIV Sales Up 4%"},"content":{"rendered":"\n<p><strong>Gilead Sciences Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/GILD:NASDAQ\">NASDAQ: GILD<\/a>) today announced its third\u2011quarter 2025 financial results. Total revenues reached <strong>$7.769\u202fbillion<\/strong>, a 3\u202f% year\u2011over\u2011year (YoY) increase, while product sales declined 2\u202f% YoY to <strong>$7.345\u202fbillion<\/strong>\u2014a drop largely driven by lower Veklury (remdesivir) and cell\u2011therapy volumes, partially offset by higher HIV and Livdelzi (seladelpar) sales. Excluding Veklury, product sales rose 4\u202f% YoY to approximately <strong>$7.1\u202fbillion<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-highlights\"><strong>Financial Highlights<\/strong><\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>Q3\u202f2025<\/th><th>YoY %<\/th><th>Notes<\/th><\/tr><\/thead><tbody><tr><td><strong>Total Revenue<\/strong><\/td><td>$7.769\u202fB<\/td><td>+3\u202f%<\/td><td><\/td><\/tr><tr><td><strong>Product Sales<\/strong><\/td><td>$7.345\u202fB<\/td><td>\u20112\u202f%<\/td><td><\/td><\/tr><tr><td><strong>Product Sales (Ex\u2011Veklury)<\/strong><\/td><td>$7.1\u202fB<\/td><td>+4\u202f%<\/td><td><\/td><\/tr><tr><td><strong>HIV Sales<\/strong><\/td><td>$5.277\u202fB<\/td><td>+4\u202f%<\/td><td><\/td><\/tr><tr><td><strong>Veklury Sales<\/strong><\/td><td>$277\u202fM<\/td><td>\u201160\u202f%<\/td><td><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-segment-performance\"><strong>Segment Performance<\/strong><\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Therapeutic Area<\/th><th>Sales<\/th><th>YoY %<\/th><th>Highlights<\/th><\/tr><\/thead><tbody><tr><td><strong>HIV<\/strong><\/td><td>$5.277\u202fB<\/td><td>+4\u202f%<\/td><td>Biktarvy up 6\u202f%; Descovy up 20\u202f%<\/td><\/tr><tr><td><strong>Cell Therapy<\/strong><\/td><td>$432\u202fM<\/td><td>\u201111\u202f%<\/td><td><\/td><\/tr><tr><td><strong>Liver Disease<\/strong><\/td><td>$819\u202fM<\/td><td>+12\u202f%<\/td><td><\/td><\/tr><tr><td><strong>Oncology (Trodelvy)<\/strong><\/td><td>$357\u202fM<\/td><td>+7\u202f%<\/td><td><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-key-product-movements\">Key Product Movements<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Biktarvy (bictegravir\u202f+\u202femtricitabine\u202f+\u202ftenofovir alafenamide)<\/strong> \u2013 $3.7\u202fB, up 6\u202f%.<\/li>\n\n\n\n<li><strong>Descovy (emtricitabine\u202f+\u202ftenofovir alafenamide)<\/strong> \u2013 $701\u202fM, up 20\u202f%.<\/li>\n\n\n\n<li><strong>Livdelzi (seladelpar)<\/strong> \u2013 growth offsetting Veklury decline.<\/li>\n\n\n\n<li><strong>Veklury (remdesivir)<\/strong> \u2013 $277\u202fM, down 60\u202f% YoY.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-developments\"><strong>Strategic Developments<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Patent Litigation Settlement<\/strong> \u2013 Gilead reached agreements with generic manufacturers that set the earliest launch of a generic Biktarvy at <strong>April\u202f1\u202f2036<\/strong>, extending exclusivity beyond the prior December\u202f2033 projection.<\/li>\n\n\n\n<li><strong>Acquisition of Interius BioTherapeutics, Inc.<\/strong> \u2013 The privately held CAR\u2011T company expands Gilead\u2019s in\u2011vivo therapeutic pipeline.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-guidance-update\"><strong>Guidance Update<\/strong><\/h2>\n\n\n\n<p>Based on the current quarter, Gilead has refined its full\u2011year 2025 product\u2011sales outlook to <strong>$28.4\u202fbillion \u2013 $28.7\u202fbillion<\/strong>, a modest upward revision from the previous $28.3\u202fbillion \u2013 $28.7\u202fbillion range.<\/p>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This release contains forward\u2011looking statements that involve risks and uncertainties. Actual results may differ materially.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Gilead Sciences Inc. (NASDAQ: GILD) today announced its third\u2011quarter 2025 financial results. Total revenues reached&#8230;<\/p>\n","protected":false},"author":1,"featured_media":45433,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[27,226,1025],"class_list":["post-45432","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-finanical-reports","tag-gilead-sciences","tag-nasdaq-gild"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Gilead Sciences Reports 3% YoY Q3\u202f2025 Revenue Growth, HIV Sales Up 4% - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Gilead Sciences Inc. (NASDAQ: GILD) today announced its third\u2011quarter 2025 financial results. Total revenues reached $7.769\u202fbillion, a 3\u202f% year\u2011over\u2011year (YoY) increase, while product sales declined 2\u202f% YoY to $7.345\u202fbillion\u2014a drop largely driven by lower Veklury (remdesivir) and cell\u2011therapy volumes, partially offset by higher HIV and Livdelzi (seladelpar) sales. Excluding Veklury, product sales rose 4\u202f% YoY to approximately $7.1\u202fbillion.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=45432\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Gilead Sciences Reports 3% YoY Q3\u202f2025 Revenue Growth, HIV Sales Up 4%\" \/>\n<meta property=\"og:description\" content=\"Gilead Sciences Inc. (NASDAQ: GILD) today announced its third\u2011quarter 2025 financial results. Total revenues reached $7.769\u202fbillion, a 3\u202f% year\u2011over\u2011year (YoY) increase, while product sales declined 2\u202f% YoY to $7.345\u202fbillion\u2014a drop largely driven by lower Veklury (remdesivir) and cell\u2011therapy volumes, partially offset by higher HIV and Livdelzi (seladelpar) sales. Excluding Veklury, product sales rose 4\u202f% YoY to approximately $7.1\u202fbillion.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=45432\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-31T07:58:43+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-31T07:58:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3112.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45432#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45432\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Gilead Sciences Reports 3% YoY Q3\u202f2025 Revenue Growth, HIV Sales Up 4%\",\"datePublished\":\"2025-10-31T07:58:43+00:00\",\"dateModified\":\"2025-10-31T07:58:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45432\"},\"wordCount\":240,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45432#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/3112.webp\",\"keywords\":[\"Finanical Reports\",\"Gilead Sciences\",\"NASDAQ: GILD\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=45432#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45432\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=45432\",\"name\":\"Gilead Sciences Reports 3% YoY Q3\u202f2025 Revenue Growth, HIV Sales Up 4% - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45432#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45432#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/3112.webp\",\"datePublished\":\"2025-10-31T07:58:43+00:00\",\"dateModified\":\"2025-10-31T07:58:44+00:00\",\"description\":\"Gilead Sciences Inc. (NASDAQ: GILD) today announced its third\u2011quarter 2025 financial results. Total revenues reached $7.769\u202fbillion, a 3\u202f% year\u2011over\u2011year (YoY) increase, while product sales declined 2\u202f% YoY to $7.345\u202fbillion\u2014a drop largely driven by lower Veklury (remdesivir) and cell\u2011therapy volumes, partially offset by higher HIV and Livdelzi (seladelpar) sales. Excluding Veklury, product sales rose 4\u202f% YoY to approximately $7.1\u202fbillion.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45432#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=45432\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45432#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/3112.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/3112.webp\",\"width\":1080,\"height\":608,\"caption\":\"Gilead Sciences Reports 3% YoY Q3\u202f2025 Revenue Growth, HIV Sales Up 4%\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45432#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Gilead Sciences Reports 3% YoY Q3\u202f2025 Revenue Growth, HIV Sales Up 4%\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Gilead Sciences Reports 3% YoY Q3\u202f2025 Revenue Growth, HIV Sales Up 4% - Insight, China&#039;s Pharmaceutical Industry","description":"Gilead Sciences Inc. (NASDAQ: GILD) today announced its third\u2011quarter 2025 financial results. Total revenues reached $7.769\u202fbillion, a 3\u202f% year\u2011over\u2011year (YoY) increase, while product sales declined 2\u202f% YoY to $7.345\u202fbillion\u2014a drop largely driven by lower Veklury (remdesivir) and cell\u2011therapy volumes, partially offset by higher HIV and Livdelzi (seladelpar) sales. Excluding Veklury, product sales rose 4\u202f% YoY to approximately $7.1\u202fbillion.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=45432","og_locale":"en_US","og_type":"article","og_title":"Gilead Sciences Reports 3% YoY Q3\u202f2025 Revenue Growth, HIV Sales Up 4%","og_description":"Gilead Sciences Inc. (NASDAQ: GILD) today announced its third\u2011quarter 2025 financial results. Total revenues reached $7.769\u202fbillion, a 3\u202f% year\u2011over\u2011year (YoY) increase, while product sales declined 2\u202f% YoY to $7.345\u202fbillion\u2014a drop largely driven by lower Veklury (remdesivir) and cell\u2011therapy volumes, partially offset by higher HIV and Livdelzi (seladelpar) sales. Excluding Veklury, product sales rose 4\u202f% YoY to approximately $7.1\u202fbillion.","og_url":"https:\/\/flcube.com\/?p=45432","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-10-31T07:58:43+00:00","article_modified_time":"2025-10-31T07:58:44+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3112.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=45432#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=45432"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Gilead Sciences Reports 3% YoY Q3\u202f2025 Revenue Growth, HIV Sales Up 4%","datePublished":"2025-10-31T07:58:43+00:00","dateModified":"2025-10-31T07:58:44+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=45432"},"wordCount":240,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=45432#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3112.webp","keywords":["Finanical Reports","Gilead Sciences","NASDAQ: GILD"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=45432#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=45432","url":"https:\/\/flcube.com\/?p=45432","name":"Gilead Sciences Reports 3% YoY Q3\u202f2025 Revenue Growth, HIV Sales Up 4% - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=45432#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=45432#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3112.webp","datePublished":"2025-10-31T07:58:43+00:00","dateModified":"2025-10-31T07:58:44+00:00","description":"Gilead Sciences Inc. (NASDAQ: GILD) today announced its third\u2011quarter 2025 financial results. Total revenues reached $7.769\u202fbillion, a 3\u202f% year\u2011over\u2011year (YoY) increase, while product sales declined 2\u202f% YoY to $7.345\u202fbillion\u2014a drop largely driven by lower Veklury (remdesivir) and cell\u2011therapy volumes, partially offset by higher HIV and Livdelzi (seladelpar) sales. Excluding Veklury, product sales rose 4\u202f% YoY to approximately $7.1\u202fbillion.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=45432#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=45432"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=45432#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3112.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3112.webp","width":1080,"height":608,"caption":"Gilead Sciences Reports 3% YoY Q3\u202f2025 Revenue Growth, HIV Sales Up 4%"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=45432#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Gilead Sciences Reports 3% YoY Q3\u202f2025 Revenue Growth, HIV Sales Up 4%"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3112.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45432","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=45432"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45432\/revisions"}],"predecessor-version":[{"id":45434,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45432\/revisions\/45434"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/45433"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=45432"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=45432"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=45432"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}